(2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2 , 42-52 /Windy Dean-Colomb, Francisco J. Esteva. (2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2 , 42-52 /...
The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal antibody. While the first line treatment has remained a combination of dual HER2 blockade with taxane chemotherapy, we now have several ex...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized disease has been chemotherapy and 1 year of adjuvant HER2-targeted therapy, typically with the anti-HER2 antibody trastuzumab. Despite the ...
HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Approximately one of every five breast cancers have a gene mutation in the cancer cells...
Sara M. Tolaney, MD, discusses the state of adjuvant treatment for patients with HER2-positive breast cancer.
Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann... S Kilickap,C Arslan - 《Annals of Oncology》 被引量: 123发表: 2009年 Treatment of HER2-Positive Metastatic Breast Cancer Following Initi...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr
metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. About MARGENZA MARGENZA is an infusion that was approved by the US Food and Drug Administration (FDA) in 2020. ...
Herceptin is approved for the treatment of adults with early-stage breast cancer that isHumanEpidermal growth factorReceptor2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the ...